RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine clesrovimab-cfor (Enflonsia) for preventing respiratory syncytial virus (RSV) in ...

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s been significantly impacted by the recent changes in FDA and HHS leadership.

CHARLOTTE — The Food and Drug Administration approved a new vaccine to help protect infants from RSV on Monday. The treatment ...

FDA approval of Merck’s RSV antibody drug, Enflonsia, makes it a direct competitor to Sanofi’s Beyfortus. The new Merck product is expected to be discussed by the CDC’s Advisory Committee on ...